Publication
Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer.
Evangelia Sereti, Susan Evans-Axelsson, Jan Törnell, Stefan Rehnmark, Marita Högberg, Anders Bjartell
Cancer chemotherapy and pharmacologySep 17, 2026PMID 42752641doi:10.1007/s00280-026-04946-1 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: This study aims to characterize the antiproliferative and antitumor activity of NOV202, a novel vascular-disrupting and microtubule-destabilizing compound, alone and in combination withthe PARP inhibitor olaparib, in preclinical prostate cancer models in vitro and in vivo. METHODS: DU145…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.